文献速递其他结缔组织病

REVEAL预后方程与风险评分计算器在系统性硬化症相关肺动脉高压中的验证

Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension.
PubMed 文献 · Arthritis Rheumatol · 2019-08-26

本研究利用约翰霍普金斯肺动脉高压项目与硬皮病注册库的前瞻性数据,在292例新诊断系统性硬化症相关肺动脉高压(SSc-PAH)患者中验证REVEAL预后方程与风险评分对1年生存的预测准确性。结果显示两种工具区分度良好(C指数分别为0.734与0.743),但校准度差,尤其在高风险组。

要点

  • REVEAL工具在SSc-PAH中区分度良好,C指数0.734-0.743。
  • 校准斜率0.707,整体模型拟合勉强(P=0.06),高风险组校准差。
  • 6分钟步行距离低与BNP高所赋风险权重低于原推导队列。

核心结论

  • REVEAL预后方程与风险评分在预测新诊断SSc-PAH患者1年生存时区分度很好但校准度差,应谨慎解读预测评分。

研究设计与样本

  • 利用约翰霍普金斯肺动脉高压项目与硬皮病注册库的前瞻性数据,在292例SSc-PAH患者中验证REVEAL模型对1年生存概率的预测准确性。

主要发现

  • 验证队列1年生存率为87.4%。
  • REVEAL预后方程的C指数为0.734(95%CI 0.652-0.816),风险评分的C指数为0.743(95%CI 0.663-0.823),区分度良好且与开发队列相当。
  • 校准斜率为0.707(95%CI 0.400-1.014),整体模型拟合勉强(P=0.06)。
  • 验证队列中6分钟步行距离低与血清BNP升高所赋的风险幅度低于REVEAL推导队列。
  • 模型校准差,尤其在高风险组。

关键数值与推荐

  • REVEAL预后方程C指数0.734(95%CI 0.652-0.816)。
  • REVEAL风险评分C指数0.743(95%CI 0.663-0.823)。
  • 校准斜率0.707(95%CI 0.400-1.014),整体模型拟合P=0.06。
  • 验证队列1年生存率87.4%。

临床怎么用

  • 在 newly diagnosed SSc-PAH 患者中可使用REVEAL工具评估1年生存风险,但需注意校准不佳,尤其对6分钟步行距离低或BNP高的高风险患者应谨慎解读评分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: A prognostic equation and risk score calculator derived from the Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management (REVEAL) are being used to predict 1-year survival in patients with pulmonary arterial hypertension (PAH), but little is known about the performance of these REVEAL survival prediction tools in systemic sclerosis (SSc)-associated PAH (SSc-PAH). METHODS: Prospectively gathered data from the Johns Hopkins Pulmonary Hypertension Program and Pulmonary Hypertension Assessment and Recognition of Outcome in Scleroderma Registries were used to evaluate the predictive accuracy of the REVEAL models for predicting the probability of 1-year survival in patients with SSc-PAH. Model discrimination was assessed by comparison of the Harrell's C-index, model fit was assessed using multivariable regression techniques, and model calibration was assessed by comparing predicted to observed survival estimates. RESULTS: The validation cohort consisted of 292 SSc-PAH patients with a 1-year survival rate of 87.4%. The C-index for predictive accuracy of the REVEAL prognostic equation (0.734, 95% confidence interval [95% CI] 0.652-0.816) and for the risk score (0.743, 95% CI 0.663-0.823) demonstrated good discrimination, comparable to that in the model development cohort. The calibration slope was 0.707 (95% CI 0.400-1.014), indicating that the overall model fit was marginal (P = 0.06). The magnitude of risk assigned to low distance on the 6-minute walk test (6MWD) and elevated serum levels of brain natriuretic peptide (BNP) was lower in the validation cohort than was originally seen in the REVEAL derivation cohort. Model calibration was poor, particularly for the highest risk groups. CONCLUSION: In predicting 1-year survival in patients newly diagnosed as having SSc-PAH, the REVEAL prognostic equation and risk score provide very good discrimination but poor calibration. REVEAL prediction scores should be interpreted with caution in newly diagnosed SSc-PAH patients, particularly those with higher predicted risk of poor 1-year survival resulting from a low 6MWD or a high BNP serum level.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mullin CJ, Khair RM, Damico RL, et al. Validation of the REVEAL Prognostic Equation and Risk Score Calculator in Incident Systemic Sclerosis-Associated Pulmonary Arterial Hypertension. Arthritis Rheumatol. 2019. PMID: 31066998. doi:10.1002/art.40918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。